Europska Unija - hrvatski - EMA (European Medicines Agency)

biogen idec ltd - declizumaba - multipla skleroza - imunosupresivi - zinbryta je indicirana kod odraslih bolesnika za liječenje relapsnih oblika multiple skleroze (rms).

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

abbvie d.o.o. - лейпрорелин - prašak i rastvarač za suspenziju za injekciju s produženim oslobađanjem - 3.75 mg/1 šprica - 1 napunjena šprica sa praškom i rastvaračem za suspenziju za injekciju s produženim oslobađanjem sadrži: 3,75 mg leuprorelina (u obliku leuprorelin acetata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

abbvie d.o.o. - лейпрорелин - prašak i rastvarač za suspenziju za injekciju s produženim oslobađanjem - 11.25 mg/1 šprica - 1 napunjena šprica sa praškom i rastvaračem za suspenziju za injekciju s produženim oslobađanjem sadrži: 11,25 mg leuprorelina (u obliku leuprorelin acetata)

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - luspatercept - anemia; myelodysplastic syndromes; beta-thalassemia - ostali lijekovi противоанемические - reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (mds) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5. reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.

Europska Unija - hrvatski - EMA (European Medicines Agency)

astrazeneca ab - chadox1-sars-cov-2 - covid-19 virus infection - cjepiva - vaxzevria is indicated for active immunisation to prevent covid 19 caused by sars cov 2, in individuals 18 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Europska Unija - hrvatski - EMA (European Medicines Agency)

alnylam netherlands b.v. - vutrisiran sodium - amyloid neuropathies, familial - ostali lijekovi protiv živčanog sustava - treatment of hereditary transthyretin-mediated amyloidosis (hattr amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.

Europska Unija - hrvatski - EMA (European Medicines Agency)

orion corporation - dexmedetomidine hydrochloride - svjesna sedacija - psycholeptics - za sedaciju odraslih intenzivnoj skrbi bolesnika zahtijeva sedaciju razini ne dublje od uzbuđenja kao odgovor na verbalne stimulacije (što odgovara za richmond agitacija-sedacija skale (rass) 0 -3).

Europska Unija - hrvatski - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - Ипилимумаб - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 i 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Europska Unija - hrvatski - EMA (European Medicines Agency)

merck sharp and dohme b.v - ribavirin - hepatitis c, kronični - antivirals for systemic use, antivirals for treatment of hcv infections - rebetol je indiciran u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa c (chc) u odraslih. Ребетол drugačije u kombinaciji s drugim lijekovima za liječenje kroničnog hepatitisa c (ХГС) za pedijatrijski pacijenti (djeca od 3 godine i starije i mlade) ne ranije uspjeli i bez jetre декомпенсация.

Europska Unija - hrvatski - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - regdanvimab - covid-19 virus infection - imuni serumi i homologna, - regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (covid-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19.